Dr. Matulonis Discusses Maintenance in Ovarian Cancer

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses maintenance therapy in ovarian cancer.

Ovarian cancer has many subgroups, says Matulonis, and successes in therapies such as PARP inhibitors can be attributed to the identification of these more specific populations.

In patients with low-grade serous cancer, aromatase inhibitors as maintenance therapy after platinum-based chemotherapy have shown an improvement in progression-free survival.